ArticleScientific reports2025
Essential oils from Artemisia judaica, Ruta graveolens and Salvia palaestina with antiradical, cytotoxic and AMPA receptor-modulatory activities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Essential oils (EOs) from the leaves of Artemisia judaica, Ruta graveolens, and Salvia palaestina were analyzed for their phytochemical composition and their antiradical, cytotoxic, and neuromodulatory activities. Using microwave-ultrasonic technology, EOs were extracted from S. palaestina, A. judaica, and R. graveolens, and their antiradical activity (via DPPH assay), cytotoxicity, and neuromodulatory effects (using whole-cell patch-clamp recordings) were evaluated. The main compounds that were explored by GC-MS analysis include piperitone and carvacrol in A. Judaica, 2-undecanone in R. graveolens, and carvacrol in S. palaestina. S. palaestina exhibited the greatest antiradical effect with a 50% inhibition concentration of 8.30 µg/mL. Cytotoxicity tests showed that these EOs express dose-dependent activity on HeLa, HepG3, and B16F1 cancer cells. Among them, S. palaestina and A. judaica were the most potent ones. Patch-clamp recordings showed that S. palaestina was the most potent in inhibiting action toward AMPA receptors, thereby reducing currents up to 6-fold and modulating receptor kinetics. A. Judaica and R. graveolens also inhibited the AMPA receptor activity, but to a lesser extent. These findings point to the important bioactive potential of these EOs, especially S. palaestina, which demonstrated high antiradical and AMPA receptor-modulatory activities and, thus, could be of interest for pharmaceutical and neuroprotective uses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.